171 related articles for article (PubMed ID: 23571475)
21. A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes.
Buikhuisen WA; Scharpfenecker M; Griffioen AW; Korse CM; van Tinteren H; Baas P
J Thorac Oncol; 2016 May; 11(5):758-768. PubMed ID: 26845191
[TBL] [Abstract][Full Text] [Related]
22. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
Dubey S; Jänne PA; Krug L; Pang H; Wang X; Heinze R; Watt C; Crawford J; Kratzke R; Vokes E; Kindler HL
J Thorac Oncol; 2010 Oct; 5(10):1655-61. PubMed ID: 20736856
[TBL] [Abstract][Full Text] [Related]
24. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Calabrò L; Morra A; Fonsatti E; Cutaia O; Amato G; Giannarelli D; Di Giacomo AM; Danielli R; Altomonte M; Mutti L; Maio M
Lancet Oncol; 2013 Oct; 14(11):1104-1111. PubMed ID: 24035405
[TBL] [Abstract][Full Text] [Related]
25. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
Scagliotti GV; Gaafar R; Nowak AK; Nakano T; van Meerbeeck J; Popat S; Vogelzang NJ; Grosso F; Aboelhassan R; Jakopovic M; Ceresoli GL; Taylor P; Orlandi F; Fennell DA; Novello S; Scherpereel A; Kuribayashi K; Cedres S; Sørensen JB; Pavlakis N; Reck M; Velema D; von Wangenheim U; Kim M; Barrueco J; Tsao AS
Lancet Respir Med; 2019 Jul; 7(7):569-580. PubMed ID: 31103412
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
Habib EE; Fahmy ES
Clin Transl Oncol; 2013 Nov; 15(11):965-8. PubMed ID: 23408040
[TBL] [Abstract][Full Text] [Related]
27. Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma.
Berardi R; Caramanti M; Fiordoliva I; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Castagnani M; Rovinelli F; Onofri A; Cascinu S
Support Care Cancer; 2015 Mar; 23(3):621-6. PubMed ID: 25142706
[TBL] [Abstract][Full Text] [Related]
28. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
[TBL] [Abstract][Full Text] [Related]
29. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; De Vincenzo F; Gianoncelli L; Simonelli M; Lorenzi E; Ripa C; Giordano L; Santoro A
Lung Cancer; 2011 Apr; 72(1):73-7. PubMed ID: 21216487
[TBL] [Abstract][Full Text] [Related]
30. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J
J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; Mencoboni M; Botta M; Grossi F; Cortinovis D; Zilembo N; Ripa C; Tiseo M; Favaretto AG; Soto-Parra H; De Vincenzo F; Bruzzone A; Lorenzi E; Gianoncelli L; Ercoli B; Giordano L; Santoro A
Br J Cancer; 2013 Aug; 109(3):552-8. PubMed ID: 23860535
[TBL] [Abstract][Full Text] [Related]
32. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
Reck M; Heigener DF; Gatzemeier U
Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
[TBL] [Abstract][Full Text] [Related]
33. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
[TBL] [Abstract][Full Text] [Related]
34. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
Jassem J; Ramlau R; Santoro A; Schuette W; Chemaissani A; Hong S; Blatter J; Adachi S; Hanauske A; Manegold C
J Clin Oncol; 2008 Apr; 26(10):1698-704. PubMed ID: 18375898
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
Castagneto B; Botta M; Aitini E; Spigno F; Degiovanni D; Alabiso O; Serra M; Muzio A; Carbone R; Buosi R; Galbusera V; Piccolini E; Giaretto L; Rebella L; Mencoboni M
Ann Oncol; 2008 Feb; 19(2):370-3. PubMed ID: 18156144
[TBL] [Abstract][Full Text] [Related]
36. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.
van den Bogaert DP; Pouw EM; van Wijhe G; Vernhout RM; Surmont VF; Hoogsteden HC; van Klaveren RJ
J Thorac Oncol; 2006 Jan; 1(1):25-30. PubMed ID: 17409823
[TBL] [Abstract][Full Text] [Related]
37. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
38. Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.
Nakano M; Kusaba H; Makiyama A; Ariyama H; Arita S; Oda H; Esaki T; Takayoshi K; Uchino K; Tamura S; Kumagai H; Iwama E; Shirakawa T; Mitsugi K; Takaishi S; Akashi K; Baba E
Anticancer Res; 2014 Jan; 34(1):215-20. PubMed ID: 24403465
[TBL] [Abstract][Full Text] [Related]
39. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
Manegold C; Symanowski J; Gatzemeier U; Reck M; von Pawel J; Kortsik C; Nackaerts K; Lianes P; Vogelzang NJ
Ann Oncol; 2005 Jun; 16(6):923-7. PubMed ID: 15824080
[TBL] [Abstract][Full Text] [Related]
40. Audit of patients with mesothelioma treated with pemetrexed in a single institution in Western Australia.
Hasani A; Feeney K; Nowak A; Millward M
Asia Pac J Clin Oncol; 2010 Dec; 6(4):350-6. PubMed ID: 21114785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]